摘要
目的观察比较替吉奥或卡培他滨联合紫杉醇治疗进展期胃癌的近期临床疗效和不良反应。方法收集符合条件的进展期胃癌患者80例,化疗方案如下:40例(观察组)患者每天给予替吉奥80 mg/m2,分2次,餐后口服,d1～d14,紫杉醇135 mg/m2,d1、d8,静脉滴注3 h,21 d为1个周期;40例(对照组)给予卡培他滨1 500 mg/m2,分2次,餐后口服,d1～d14,紫杉醇135 mg/m2,d1、d8,静脉滴注3 h,21 d为1个周期。至少完成2个周期,按RECIST1.1标准评价客观疗效,按WHO标准评价不良反应。结果观察组与对照组的有效率(RR)分别为60.0%和37.5%,差异有统计学意义(χ2=4.053,P=0.044)。临床获益率(DCR)分别为80.0%和77.5%,差异无统计学意义(χ2=0.075,P=0.785)。两组主要不良反应为骨髓抑制及胃肠道反应,但差异均无统计学意义。结论替吉奥联合紫杉醇治疗进展期胃癌疗效较好,可以提高有效率,且不良反应可以耐受,值得临床进一步研究应用。
Objective To assess the recent efficacy and adverse reaction of paclitaxel combined with capecitabine or tegafur in the treatment of advanced gastric cancer. Methods According to condition eighty advanced gastric cancer patients were collected. The chemotherapy planed as follows： Forty patient （observation group） were got tegafur 80 mg/m2, orally twice daily, dl-dl4, paclitaxel 135 mg/m2 ivgtt 3 h, dl and d8, repeated every 21 d; Forty patients （control group） were got capecitabine 1 500 mg/m~, orally twice daily, dl-dl4, paclitaxel 135 mg/m2 ivgtt 3 h, dl and d8, repeated every 21 d. All patients received two cycles of chemotherapy at least. The efficacy was evaluated according to RECIST standard and toxicity was evaluated according to WHO standard. Results The effective percentage （RR） of the observation group and the control group were 60.0% and 37.5%; There was significant difference between the two groups （χ2=4.053, P = 0.044）. The clinical benefit rate （DCR） were 80.0% and 77.5%; There was no significant difference between the two groups （χ2=0.075, P = 0.785）. The main adverse events were bone marrow suppression and gastrointestinal reaction, but there was no significant difference between two groups. Conclusion The efficacy of paclitaxel combined with tegafur is better in the treatment of advanced gastric cancer, and can elevate the effective percentage. The side effects are mild and tolerable. It is worthy of further research and application.
出处
《中国现代医生》
2012年第5期66-67,69,共3页
China Modern Doctor
关键词
胃癌
替吉奥
紫杉醇
卡培他滨
Gastric cancer
Tegafur
Paclitaxel
Capecitabine
